Alexandra Lansky, MD
Cardiology · New Haven, CTNPI 1336227172
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (41.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Shockwave Medical, Inc at 36.0% of the total. 2025 is the largest year on record at $69,644, 2.4 times the $29,180 reported in 2019. Among cardiology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 147 payments — averaging $1328.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shockwave Medical, Inc$70K
- Abiomed$33K
- Trireme Medical LLC$21K
- Merit Medical Systems Inc$18K
- AstraZeneca$17K
- Boston Scientific$15K
- plus $22K from 9 others
Across 118 payments — averaging $31,062 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Trireme Medical LLC$872K
- Siemens Medical Solutions USA, Inc.$692K
- Cleerly, Inc.$603K
- Bard Peripheral Vascular, Inc.$466K
- Surmodics, Inc.$417K
- Contego Medical, Inc$390K
- plus $227K from 10 others
What the payments were for
- Consulting fees$67,71835%
- Speaking & faculty fees$81,67042%
- Travel & lodging$42,96322%
- Food & beverage$2,9041%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shockwave Medical, Inc | 53 | $70,388 |
| Abiomed | 25 | $32,553 |
| Trireme Medical LLC | 6 | $20,605 |
| Merit Medical Systems Inc | 4 | $18,130 |
| AstraZeneca | 16 | $17,167 |
| Boston Scientific | 10 | $14,583 |
| Recor Medical Inc | 8 | $6,943 |
| Abbott | 7 | $4,085 |
| Angiodynamics, Inc. | 7 | $3,864 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $3,141 |
| Infraredx, Inc. | 2 | $1,655 |
| B. Braun Interventional Systems Inc. | 1 | $1,400 |
| Amgen | 1 | $496 |
| Jenavalve Technology, Inc. | 1 | $160 |
| Edwards Lifesciences | 3 | $95 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$69,638
- Impella$21,445
- Wrapsody Stent Graft$18,130
- BRILINTA$15,704
- Sentinel$10,375
- Chocolate Touch$9,693
- Paradise Ultrasound Renal Denervation System$6,919
- LifeVest$3,046
- AlphaVac$2,053
- AngioVac$1,781
- SEQUENT PLEASE REX DRUG COATED PTCA CATHETER$1,400
- Watchman$1,000
- Vascular Lithotripsy$750
- Repatha$496
- OPTIS$180
- JenaValve Pericardial TAVR System$160
- Mitra Clip system$149
How this compares
$195,264 in reported general payments places this provider in the 95th percentile of 28 cardiology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 21 | $26,152 |
| FarxigaDapagliflozin Propanediol | 17 | $16,121 |
| Valsartan | 24 | $843 |
| Metoprolol Succinate | 49 | $720 |
| Atorvastatin Calcium | 67 | $528 |
| Rosuvastatin Calcium | 37 | $354 |
| ClopidogrelClopidogrel Bisulfate | 25 | $295 |
| Losartan Potassium | 42 | $284 |
| Ezetimibe | 21 | $169 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 11 | $157 |
| Amlodipine Besylate | 28 | $132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $17,167 | $16,12117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 28 cardiology providers in Connecticut.
Other cardiology in New Haven
- Shashank JainNew Haven$14K
- Elise MeoliNew Haven$0
- Arya ManiNew Haven$0
- Thomas DonohueNew Haven$0
- Oliver WangNew Haven$0
- Mark SchoenfeldNew Haven$0
- Kamil FaridiNew Haven$0
- Filipe MouraNew Haven$0
- Lawrence YoungNew Haven$0
- Neiberg de Alcantara LimaWillimantic$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.